Across TCGA pan-cancer cohorts, OR10R2 Mutation is linked to patient survival in 5 of 34 cancer types, making it the most broadly survival-associated OR10R2 data layer compared with 3 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher OR10R2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated OR10R2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

SKCM, STAD, and COAD are the cancer types where OR10R2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	III,IV	1.000	0.450	.002	19	view →
STAD	DFS	Median	II,III,IV	0.112	0.615	<.001	15	view →
COAD	OS	Median	IV	0.082	0.659	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.628	.022	6	view →
LIHC	OS	Median	All	0.144	0.704	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: OR10R2 tumor-vs-normal RNA expression · all OR10R2 data types